

**Announcement  
21 March 2011****Coloplast – transactions in connection with share buy-back programme**

As mentioned in Announcement No. 2/2011 Coloplast is currently exercising a share buy-back programme of DKK 1 billion. The first part of this programme was implemented in 2010 while the second part with a total scope of up to DKK 500 million is expected to be exercised in the period 14 February – 30 September 2011.

Under the programme the following transactions have been executed during the period 14 – 18 March 2011:

<b>Date</b>	<b>Number of shares</b>	<b>Average buying price</b>	<b>Amount DKK</b>
14.3.2011	6,750	725,99	4,900,432.50
15.3.2011	6,489	712,21	4,621,530.69
16.3.2011	14,262	715,88	10,209,880.56
17.3.2011	4,075	707,23	2,881,962.25
18.3.2011	0.00	-	0.00
<b>Accumulated until now under the programme</b>	226,022	753.95	170,408,301.41

Henceforth, Coloplast owns 2,876,795 own B shares of DKK 5 equal to 6.39% of the company's total share capital.

Share buy-back in the amount of 329,591,698.59 remains under the first part of the programme.

## **For further information, please contact**

### **Investors and analysts**

Lene Skole  
Executive Vice President, CFO  
Tel. +45 4911 1700

Ian S.E. Christensen  
Director of Investor Relations  
Tel. +45 4911 1800/+45 4911 1301  
Email: dkisec@coloplast.com

Henrik Nord  
Investor Relations Manager  
Tel. +45 4911 1800/+45 4911 3108  
Email: dkhno@coloplast.com

### **Press and the media**

Ulla Lundhus  
Media Relations Manager  
Tel. +45 4911 1929  
Email: dkul@coloplast.com

This announcement is available in a Danish and an English-language version.  
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2011-03 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology and Continence Care and Wound and Skin Care. We operate globally and employ more than 7,000 people.